CoChat
Sign Up
Cited by 32

The DOI matches its Crossref record.

Magnetoliposomes of mixed biomimetic and inorganic magnetic nanoparticles as enhanced hyperthermia agents

Jabalera, Ylenia, Fernández-Vivas, Antonia, Iglesias, Guillermo R., Delgado, Ángel V., Jimenez-Lopez, Concepcion·2019·Colloids and Surfaces B: Biointerfaces
DOI 10.1016/j.colsurfb.2019.110435
Open this paper in CoChat — free account

Abstract

Recently, liposomes have been explored as a potential solution to improve the biocompatibility and the colloidal stability of magnetic nanoparticles. Protocols have been developed for producing magnetoliposomes of magnetite nanoparticles obtained inorganically (MNPs). However, the biomimetic synthesis of magnetite using heterologous proteins from magnetotactic bacteria has become a real alternative to produce novel biomimetic magnetic nanoparticles (BMNPs). Among these, the BMNPs obtained in presence of MamC protein from Magnetococcus marinus MC-1 have been proposed as excellent candidates to be potentially used as drug nanocarriers and as hyperthermia agents. However, their colloidal stability still needs to be improved while maintaining their magnetic properties intact. One possibility explored in this manuscript is to form magnetoliposomes that contain BMNPs. Indeed, the protocols developed for producing magnetoliposomes of MNPs need to be tested and modified to be able to include BMNPs. In this context, a protocol has been developed to produce both magnetoliposomes filled with MNPs and/or BMNPs and their potential as hyperthermia agents was tested. In fact, for the first time, these two types of nanoparticles were mixed in different proportions to test the composition that would optimize such as behaviour as hyperthermia agents. Interestingly, it was observed that the hyperthermia behaviour of the magnetoliposomes greatly improved if they were filled with a mixture of MNP…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.colsurfb.2019.110435

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 57

  1. Shubayev, 2009, Magnetic nanoparticles for theragnostics, Adv. Drug Deliv. Rev., 61, 467, 10.1016/j.addr.2009.03.007 · DOI
  2. Prozorov, 2013, Novel magnetic nanomaterials inspired by magnetotactic bacteria: topical review, Mater. Sci. Eng. R Rep., 74, 133, 10.1016/j.mser.2013.04.002 · DOI · Paper page
  3. Mody, 2014, Magnetic nanoparticle drug delivery systems for targeting tumor, Appl. Nanosci., 4, 385, 10.1007/s13204-013-0216-y · DOI
  4. Pankhurst, 2003, Applications of magnetic nanoparticles in biomedicine, J. Phys. D-Applied Phys., 36, R167, 10.1088/0022-3727/36/13/201 · DOI
  5. Alphandéry, 2011, Heat production by bacterial magnetosomes exposed to an oscillating magnetic field, J. Phys. Chem. C., 115, 18, 10.1021/jp104580t · DOI
  6. Soares, 2012, Application of hyperthermia for cancer treatment: recent patents review, Recent Pat. Anticancer Drug Discov., 7, 64, 10.2174/157489212798358038 · DOI
  7. Li, 2017, Correlation between particle size/domain structure and magnetic properties of highly crystalline Fe3O4 nanoparticles, Sci. Rep., 7, 9894, 10.1038/s41598-017-09897-5 · DOI
  8. Valverde-Tercedor, 2015, Size control of in vitro synthesized magnetite crystals by the MamC protein of Magnetococcus marinus strain MC-1, Appl. Microbiol. Biotechnol., 99, 5109, 10.1007/s00253-014-6326-y · DOI · Paper page
  9. Amemiya, 2007, Controlled formation of magnetite crystal by partial oxidation of ferrous hydroxide in the presence of recombinant magnetotactic bacterial protein Mms6, Biomaterials, 28, 5381, 10.1016/j.biomaterials.2007.07.051 · DOI
  10. Arakaki, 2010, Control of the morphology and size of magnetite particles with peptides mimicking the Mms6 protein from magnetotactic bacteria, J. Colloid Interface Sci., 343, 65, 10.1016/j.jcis.2009.11.043 · DOI
  11. Prozorov, 2007, Protein-mediated synthesis of uniform superparamagnetic magnetite nanocrystals, Adv. Funct. Mater., 17, 951, 10.1002/adfm.200600448 · DOI
  12. Galloway, 2011, Magnetic bacterial protein Mms6 controls morphology, crystallinity and magnetism of cobalt-doped magnetite nanoparticles in vitro, J. Mater. Chem., 21, 15244, 10.1039/c1jm12003d · DOI
  13. Arakaki, 2003, A novel protein tightly bound to bacterial magnetic particles in Magnetospirillum magneticum strain AMB-1, J. Biol. Chem., 278, 8745, 10.1074/jbc.M211729200 · DOI
  14. Lopez-Moreno, 2017, Magnetite nanoparticles biomineralization in the presence of the magnetosome membrane protein MamC: effect of protein aggregation and protein structure on magnetite formation, Cryst. Growth Des., 17, 1620, 10.1021/acs.cgd.6b01643 · DOI · Paper page
  15. Nudelman, 2016, Structure – function studies of the magnetite-biomineralizing magnetosome-associated protein MamC, J. Struct. Biol., 194, 1, 10.1016/j.jsb.2016.03.001 · DOI
  16. Jabalera, 2019, Protein conservation method affects MamC-mediated biomineralization of magnetic nanoparticles, Cryst. Growth Des., 19, 1064, 10.1021/acs.cgd.8b01590 · DOI
  17. García Rubia, 2018, pH-dependent adsorption release of doxorubicin on MamC-Biomimetic magnetite nanoparticles, Langmuir, 34, 13713, 10.1021/acs.langmuir.8b03109 · DOI · Paper page
  18. Functionalized biomimetic magnetic nanoparticles as effective nanocarriers for targeted chemotherapy (in press), Part. Part. Syst. Charact. (n.d.).
  19. Sun, 2011, Bacterial magnetosome: a novel biogenetic magnetic targeted drug carrier with potential multifunctions, J. Nanomater., 2011, 1
  20. Alphandéry, 2014, Applications of magnetosomes synthesized by magnetotactic bacteria in medicine, Front. Bioeng. Biotechnol., 2, 1
  21. Soenen, 2009, Addressing the problem of cationic lipid-mediated toxicity: the magnetoliposome model, Biomaterials, 30, 3691, 10.1016/j.biomaterials.2009.03.040 · DOI
  22. Martina, 2005, Generation of superparamagnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging, J. Am. Chem. Soc., 127, 10676, 10.1021/ja0516460 · DOI
  23. Sabaté, 2008, Preparation and characterization of extruded magnetoliposomes, Int. J. Pharm., 347, 156, 10.1016/j.ijpharm.2007.06.047 · DOI
  24. García-Jimeno, 2011, Magnetoliposomes prepared by reverse-phase followed by sequential extrusion: characterization and possibilities in the treatment of inflammation, Int. J. Pharm., 405, 181, 10.1016/j.ijpharm.2010.11.044 · DOI
  25. Bothun, 2011, Multicomponent folate-targeted magnetoliposomes: design, characterization, and cellular uptake, Nanomedicine Nanotechnology, Biol. Med., 7, 797
  26. Garnier, 2012, Optimized synthesis of 100 nm diameter magnetoliposomes with high content of maghemite particles and high MRI effect, Contrast Media Mol. Imaging, 7, 231, 10.1002/cmmi.487 · DOI
  27. Clares, 2013, Nano-engineering of 5-fluorouracil-loaded magnetoliposomes for combined hyperthermia and chemotherapy against colon cancer, Eur. J. Pharm. Biopharm., 85, 329, 10.1016/j.ejpb.2013.01.028 · DOI
  28. German, 2015, Liposomes loaded with hydrophilic magnetite nanoparticles: preparation and application as contrast agents for magnetic resonance imaging, Colloids Surf. B Biointerfaces, 135, 109, 10.1016/j.colsurfb.2015.07.042 · DOI
  29. Joniec, 2016, Magnetoliposomes as potential carriers of doxorubicin to Tumours, Chem. - A Eur. J., 22, 17715, 10.1002/chem.201602809 · DOI
  30. Nappini, 2016, Magnetic field responsive drug release from magnetoliposomes in biological fluids, J. Mater. Chem. B Mater. Biol. Med., 4, 716, 10.1039/C5TB02191J · DOI
  31. Cho, 2008, Therapeutic nanoparticles for drug delivery in cancer, Clin. Cancer Res., 14, 1310, 10.1158/1078-0432.CCR-07-1441 · DOI
  32. Durán, 2008, Magnetic colloids as drug vehicles, J. Pharm. Sci., 97, 2948, 10.1002/jps.21249 · DOI
  33. Soenen, 2011, Magnetoliposomes as magnetic resonance imaging contrast agents, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 3, 197, 10.1002/wnan.122 · DOI
  34. Jesorka, 2008, Liposomes: technologies and analytical applications, Annu. Rev. Anal. Chem., 1, 801, 10.1146/annurev.anchem.1.031207.112747 · DOI
  35. Abenojar, 2016, Structural effects on the magnetic hyperthermia properties of iron oxide nanoparticles, Prog. Nat. Sci. Mater. Int., 26, 440, 10.1016/j.pnsc.2016.09.004 · DOI
  36. Di Corato, 2014, Magnetic hyperthermia efficiency in the cellular environment fordifferent nanoparticle designs, Biomaterials, 35, 6400, 10.1016/j.biomaterials.2014.04.036 · DOI
  37. Reddy, 2012, Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications, Chem. Rev., 112, 5818, 10.1021/cr300068p · DOI · Paper page
  38. Perez-Gonzalez, 2010, Inorganic magnetite precipitation at 25 °C: a low-cost inorganic coprecipitation method, J. Supercond. Nov. Magn., 24, 549, 10.1007/s10948-010-0999-y · DOI
  39. Wildeboer, 2014, On the reliable measurement of specific absorption rates and intrinsic loss parameters in magnetic hyperthermia materials, J. Phys. D Appl. Phys., 47, 10.1088/0022-3727/47/49/495003 · DOI
  40. Gonzales, 2005, Synthesis of magnetoliposomes with monodisperse iron oxide nanocrystal cores for hyperthermia, J. Magn. Magn. Mater., 265, 10.1016/j.jmmm.2005.02.020 · DOI
  41. Babincová, 2002, AC-magnetic field controlled drug release from magnetoliposomes: design of a method for site-specific chemotherapy, Bioelectrochemistry, 55, 17, 10.1016/S1567-5394(01)00171-2 · DOI
  42. Muñoz de Escalona, 2016, Magnetic solid lipid nanoparticles in hyperthermia against colon cancer, Int. J. Pharm., 504, 11, 10.1016/j.ijpharm.2016.03.005 · DOI
  43. Kulshrestha, 2012, In vitro application of paclitaxel loaded magnetoliposomes for combined chemotherapy and hyperthermia, Colloids Surf. B Biointerfaces, 96, 1, 10.1016/j.colsurfb.2012.02.029 · DOI
  44. G. Lle Beálle, R. Di Corato, J. Kolosnjaj-Tabi, V. Dupuis, O. Cleent, F. Gazeau, C. Wilhelm, C. Meager, Ultra Magnetic Liposomes for MR Imaging, Targeting, and Hyperthermia, (n.d.). doi:10.1021/la3024716. · DOI
  45. Nappini, 2011, Magnetically triggered release from giant unilamellar vesicles: visualization by means of confocal microscopy, J. Phys. Chem. Lett., 2, 713, 10.1021/jz2000936 · DOI
  46. Laurent, 2008, Magnetic Iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications, Chem. Rev., 108, 2064, 10.1021/cr068445e · DOI · Paper page
  47. Cheraghipour, 2012, Citrate capped superparamagnetic iron oxide nanoparticles used for hyperthermia therapy, J. Biomed. Sci. Eng., 05, 715, 10.4236/jbise.2012.512089 · DOI
  48. Lesieur, 2003, Evidence of surfactant-induced formation of transient pores in lipid bilayers by using magnetic-fluid-loaded liposomes, J. Am. Chem. Soc., 125, 5266, 10.1021/ja021471j · DOI
  49. Vikesland, 2016, Aggregation and sedimentation of magnetite nanoparticle clusters, Environ. Sci. Nano, 3, 567, 10.1039/C5EN00155B · DOI
  50. Li, 2010, Magnetite nanoparticles with high heating efficiencies for application in the hyperthermia of cancer, Mater. Sci. Eng. C., 30, 990, 10.1016/j.msec.2010.04.016 · DOI
  51. Shaterabadi, 2018, Physics responsible for heating efficiency and self-controlled temperature rise of magnetic nanoparticles in magnetic hyperthermia therapy, Prog. Biophys. Mol. Biol., 133, 9, 10.1016/j.pbiomolbio.2017.10.001 · DOI
  52. Obaidat, 2015, Magnetic properties of magnetic nanoparticles for efficient hyperthermia, Nanomaterials, 5, 63, 10.3390/nano5010063 · DOI
  53. Huber, 2005, Synthesis, properties, and applications of iron nanoparticles, Small, 1, 482, 10.1002/smll.200500006 · DOI
  54. Salvatore, 2016, Multifunctional magnetoliposomes for sequential controlled release, ACS Nano, 10, 7749, 10.1021/acsnano.6b03194 · DOI
  55. Spera, 2014, Controlled release from magnetoliposomes aqueous suspensions exposed to a low intensity magnetic field, Bioelectromagnetics, 35, 309, 10.1002/bem.21841 · DOI
  56. Chen, 2010, Controlled release from bilayer-decorated magnetoliposomes via electromagnetic heating, ACS Nano, 4, 3215, 10.1021/nn100274v · DOI
  57. Torchilin, 2005, Recent advances with liposomes as pharmaceutical carriers, Nat. Rev. Drug Discov., 4, 145, 10.1038/nrd1632 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Jabalera, Y., Fernández-Vivas, A., Iglesias, G. R., Delgado, Á. V., & Jimenez-Lopez, C.
ORCID
Venue
Colloids and Surfaces B: Biointerfaces
Publisher
Elsevier BV
Published
2019-11
Volume
183
Pages
110435
ISSN
0927-7765
DOI
10.1016/j.colsurfb.2019.110435
Cited by
32
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review